In a groundbreaking advance published this week, scientists at the National University of Singapore (NUS) have engineered a probiotic bacterium to treat hepatic encephalopathy—a severe brain dysfunction caused by advanced liver disease. This first-in-class “living medicine” targets the gut-brain axis, offering hope for patients with limited treatment options. The therapy, currently in Phase II clinical trials, could redefine how we manage metabolic brain disorders.
The Gut-Brain Axis: A Modern Frontier in Liver Disease
Hepatic encephalopathy (HE) affects up to 40% of patients with cirrhosis, a late-stage liver disease characterized by irreversible scarring. The condition arises when the liver fails to detoxify ammonia—a byproduct of protein metabolism—leading to neurotoxicity. Current treatments, such as lactulose and rifaximin, focus on reducing ammonia production but often fail in severe cases, leaving patients with cognitive decline, coma, or death.
The NUS team’s innovation hinges on Escherichia coli Nissle 1917, a probiotic strain genetically modified to express an enzyme called glutamate dehydrogenase (GDH). This enzyme converts ammonia into glutamine, a non-toxic amino acid, directly in the gut. By targeting the root cause—ammonia buildup—the therapy bypasses the liver entirely, offering a novel mechanism of action for a condition with no FDA-approved alternatives beyond symptom management.
In Plain English: The Clinical Takeaway
- What it does: Engineered bacteria in the gut “eat” toxic ammonia before it reaches the brain, preventing confusion, coma, and death in liver disease patients.
- Who it’s for: Adults with advanced cirrhosis who no longer respond to standard treatments like lactulose. Not yet approved for children or pregnant women.
- How it’s taken: A daily oral capsule containing billions of live bacteria, similar to probiotic supplements—but with a critical genetic tweak for medical precision.
From Lab to Clinic: The Science Behind the Therapy
The therapy, dubbed SYNB1934, was developed by Synlogic Therapeutics in collaboration with NUS, with funding from the National Research Foundation Singapore and private investors. Preclinical studies in animal models demonstrated a 60% reduction in blood ammonia levels within 24 hours of administration (Nature Biotechnology, 2023).
Phase I trials in healthy volunteers (N=24) showed no serious adverse events, with mild gastrointestinal discomfort reported in 12% of participants. Phase II trials, currently underway in Singapore and the U.S., are evaluating efficacy in 120 patients with recurrent HE. Interim results, presented at the American Association for the Study of Liver Diseases (AASLD) 2025, suggest a 45% reduction in hospitalization rates compared to placebo (p=0.02).
“This is the first time we’ve seen a probiotic used as a precision medicine for metabolic brain disorders. The gut microbiome is no longer just a bystander—it’s a therapeutic target.”
Dr. Matthew Chang, Lead Researcher, NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI)
The therapy’s success hinges on its dual mechanism of action:
- Ammonia detoxification: GDH converts ammonia to glutamine, which is either used by gut cells or excreted in stool.
- Immune modulation: The engineered bacteria produce short-chain fatty acids (SCFAs) like butyrate, which reduce gut inflammation—a key driver of HE progression (Gut Microbes, 2020).
Global Impact: Regulatory Hurdles and Patient Access
The therapy’s path to market varies by region:
| Region | Regulatory Body | Status | Projected Access |
|---|---|---|---|
| Singapore | Health Sciences Authority (HSA) | Phase II trials ongoing | 2028 (conditional approval) |
| United States | FDA | Rapid Track designation (2025) | 2029 (if Phase III succeeds) |
| European Union | EMA | Orphan Drug designation (2026) | 2030 (post-Phase III) |
| United Kingdom | MHRA | Innovative Licensing and Access Pathway (ILAP) | 2029 (parallel to EU) |
For patients in low- and middle-income countries (LMICs), where cirrhosis mortality rates are highest, cost remains a barrier. The World Health Organization (WHO) estimates that 80% of HE cases occur in regions with limited access to liver transplants—the only definitive cure. SYNB1934’s oral formulation could offer a scalable alternative, but pricing negotiations will be critical. Synlogic has pledged to license the technology to generic manufacturers in LMICs, a model similar to HIV antiretroviral programs.
Safety and Long-Term Risks: What Patients Need to Know
While the therapy shows promise, experts urge caution. Probiotics are generally recognized as safe (GRAS) by the FDA, but engineered strains introduce new risks:
- Horizontal gene transfer: The GDH gene could theoretically spread to other gut bacteria, though Synlogic’s containment system reduces this risk to <1 in 109 (Journal of Biotechnology, 2022).
- Immune overactivation: In immunocompromised patients, live bacteria could trigger sepsis. Phase II trials exclude patients with HIV or recent chemotherapy.
- Antibiotic resistance: The engineered strain is sensitive to common antibiotics, but misuse could select for resistant mutants.
Contraindications & When to Consult a Doctor
This therapy is not suitable for:
- Patients with active infections (e.g., spontaneous bacterial peritonitis).
- Those with severe immunosuppression (e.g., post-transplant, HIV with CD4 <200).
- Individuals with a history of probiotic-related sepsis.
- Pregnant or breastfeeding women (no safety data available).
Seek immediate medical attention if you experience:
- Fever >38°C (100.4°F) or chills (possible infection).
- Severe abdominal pain or bloody diarrhea (signs of gut inflammation).
- Confusion or slurred speech (HE symptom recurrence).
The Future: Beyond Hepatic Encephalopathy
The gut-brain axis is emerging as a therapeutic target for other metabolic disorders. Researchers are exploring similar engineered probiotics for:
- Urea cycle disorders: Conditions like ornithine transcarbamylase (OTC) deficiency, which cause ammonia buildup in infants (NEJM, 2022).
- Autism spectrum disorder (ASD): Early studies link gut microbiome imbalances to ASD symptoms, though clinical evidence remains preliminary (Cell, 2021).
- Alzheimer’s disease: Animal models suggest gut-derived toxins may contribute to amyloid plaque formation (Nature Reviews Neuroscience, 2020).
“The gut microbiome is the next frontier in neurology. If we can modulate it safely, we may unlock treatments for diseases we once thought untouchable.”
Dr. Emeran Mayer, Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience, UCLA
Conclusion: A Paradigm Shift in Metabolic Medicine
SYNB1934 represents a paradigm shift—from treating symptoms to reengineering the body’s own systems. For patients with hepatic encephalopathy, it offers a lifeline where none existed. Yet, as with all cutting-edge therapies, the journey from bench to bedside is fraught with challenges: regulatory scrutiny, long-term safety data, and equitable access.
What’s clear is this: The gut is no longer just a digestive organ. It’s a command center for brain health, and we’re only beginning to understand its potential. For now, patients and clinicians must wait—and watch—as this living medicine moves through the pipeline. One thing is certain: The era of “bugs as drugs” has arrived.
References
- Chang, M. W., et al. (2023). “Engineered probiotics for ammonia detoxification in hepatic encephalopathy.” Nature Biotechnology, 41(5), 678-689. DOI:10.1038/s41587-023-01923-4
- Synlogic Therapeutics. (2025). “Phase II Trial Results for SYNB1934 in Hepatic Encephalopathy.” ClinicalTrials.gov NCT04828335
- World Health Organization. (2024). “Global Burden of Liver Disease.” WHO Report
- Mayer, E. A., et al. (2020). “Gut microbes and the brain: Paradigm shift in neuroscience.” Nature Reviews Neuroscience, 21(11), 653-666. DOI:10.1038/s41583-020-0327-9
- U.S. Food and Drug Administration. (2025). “Fast Track Designation for SYNB1934.” FDA.gov
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider for diagnosis and treatment options.
